John Wayne Cancer InstituteCancer Institute: Allovectin-7® May Offer Patients a New Option for Advanced Melanoma
05 Dec 2007
ASCO
SANTA MONICA, Calif.--(BUSINESS WIRE)--Skin cancer specialists at The John Wayne Cancer InstituteCancer Institute at Saint John’s Health Center are recruiting patients into a large Phase 3 study to evaluate the safety and effectiveness of Allovectin-7®, an investigational product for advanced melanoma. If Allovectin-7® is found to be safe and effective in clinical trials, it may offer patients a new option for fighting advanced melanoma (stage 3 or stage 4). Safety and efficacy data from a Phase 2 clinical trial of Allovectin-7® were presented at the 2006 American Society of Clinical Oncology (ASCO) meeting. The ongoing Phase 3 study is designed to determine whether more patients with advanced melanoma respond favorably to Allovectin-7® alone than to current standard chemotherapy alone. To find out whether you or someone you know qualifies for the study, please visit
Organizations
Indications
Targets
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.